TY  - JOUR
A1  - Whitehead, Mark
A1  - Öhlschläger, Peter
A1  - Almajhdi, Fahad N.
A1  - Alloza, Leonor
A1  - Marzábal, Pablo
A1  - Meyers, Ann E.
A1  - Hitzeroth, Inga I.
A1  - Rybicki, Edward P.
T1  - Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice
JF  - BMC cancer
Y1  - 2014
U6  - http://dx.doi.org/10.1186/1471-2407-14-367
SN  - 1471-2407
IS  - 14:367
SP  - 1
EP  - 15
PB  - BioMed Central
CY  - London
ER  - 
TY  - JOUR
A1  - Öhlschläger, Peter
A1  - Quetting, Michael
A1  - Alvarez, Gerardo
A1  - Dürst, Matthias
A1  - Gissmann, Lutz
A1  - Kaufmann, Andreas M.
T1  - Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants
JF  - International Journal of Cancer
Y1  - 2009
SN  - 1097-0215
VL  - 125
IS  - 1
SP  - 189
EP  - 198
PB  - Wiley
CY  - Weinheim
ER  - 
TY  - JOUR
A1  - Manea, Marilena
A1  - Leurs, Ulrike
A1  - Orban, Erika
A1  - Baranyai, Zsuzsa
A1  - Öhlschläger, Peter
A1  - Marquardt, Andreas
A1  - Schulcz, Akos
A1  - Tejeda, Miguel
T1  - Enhanced Enzymatic Stability and Antitumor Activity of Daunorubicin-GnRH-III Bioconjugates Modified in Position 4
JF  - Bioconjugate Chemistry
Y1  - 2011
SN  - 1520-4812
VL  - 22
IS  - 7
SP  - 1320
EP  - 1329
PB  - ACS
CY  - Washington, DC
ER  - 
TY  - CHAP
A1  - Takenaga, Shoko
A1  - Herrera, Cony F.
A1  - Werner, Frederik
A1  - Biselli, Manfred
A1  - Schnitzler, Thomas
A1  - Schöning, Michael Josef
A1  - Öhlschläger, Peter
A1  - Wagner, Torsten
T1  - Detection of the metabolic activity of cells by differential measurements based on a single light-addressable potentiometric sensor chip
T2  - 11. Dresdner Sensor-Symposium : 9.-11.12.2013
Y1  - 2013
SN  - 978-3-9813484-5-3
SP  - 63
EP  - 67
ER  - 
TY  - JOUR
A1  - Leurs, Ulrike
A1  - Mezo, Gabor
A1  - Öhlschläger, Peter
A1  - Orban, Erika
A1  - Marquard, Andrea
A1  - Manea, Marilena
T1  - Design, synthesis, in vitro stability and cytostatic effect of multifunctional anticancer drug-bioconjugates containing GnRH-III as a targeting moiety
JF  - Peptide Science
N2  - Bioconjugates containing the GnRH-III hormone decapeptide as a targeting moiety are able to deliver chemotherapeutic agents specifically to cancer cells expressing GnRH receptors, thereby increasing their local efficacy while limiting the peripheral toxicity. However, the number of GnRH receptors on cancer cells is limited and they desensitize under continuous hormone treatment. A possible approach to increase the receptor mediated tumor targeting and consequently the cytostatic effect of the bioconjugates would be the attachment of more than one chemotherapeutic agent to one GnRH-III molecule. Here we report on the design, synthesis and biochemical characterization of multifunctional bioconjugates containing GnRH-III as a targeting moiety and daunorubicin as a chemotherapeutic agent. Two different drug design approaches were pursued. The first one was based on the bifunctional [4Lys]-GnRH-III (Glp-His-Trp-Lys-His-Asp-Trp-Lys-Pro-Gly-NH2) containing two lysine residues in positions 4 and 8, whose ϵ-amino groups were used for the coupling of daunorubicin. In the second drug design, the native GnRH-III (Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2) was used as a scaffold; an additional lysine residue was coupled to the ϵ-amino group of 8Lys in order to generate two free amino groups available for conjugation of daunorubicin. The in vitro stability/degradation of all synthesized compounds was investigated in human serum, as well as in the presence of rat liver lysosomal homogenate. Their cellular uptake was determined on human breast cancer cells and the cytostatic effect was evaluated on human breast, colon and prostate cancer cell lines. Compared with a monofunctional compound, both drug design approaches resulted in multifunctional bioconjugates with increased cytostatic effect.
Y1  - 2012
U6  - http://dx.doi.org/10.1002/bip.21640
SN  - 1097-0282
VL  - 98
IS  - 1
SP  - 1
EP  - 10
PB  - Wiley
CY  - New York, NY
ER  - 
TY  - JOUR
A1  - Almajhdi, Fahad N.
A1  - Senger, Tilo
A1  - Amer, Haitham M.
A1  - Gissmann, Lutz
A1  - Öhlschläger, Peter
T1  - Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (Shuffling)
JF  - PLOS one
N2  - Persistent infection with the high-risk Human Papillomavirus type 16 (HPV 16) is the causative event for the development of cervical cancer and other malignant tumors of the anogenital tract and of the head and neck. Despite many attempts to develop therapeutic vaccines no candidate has entered late clinical trials. An interesting approach is a DNA based vaccine encompassing the nucleotide sequence of the E6 and E7 viral oncoproteins. Because both proteins are consistently expressed in HPV infected cells they represent excellent targets for immune therapy. Here we report the development of 8 DNA vaccine candidates consisting of differently rearranged HPV-16 E6 and E7 sequences within one molecule providing all naturally occurring epitopes but supposedly lacking transforming activity. The HPV sequences were fused to the J-domain and the SV40 enhancer in order to increase immune responses. We demonstrate that one out of the 8 vaccine candidates induces very strong cellular E6- and E7- specific cellular immune responses in mice and, as shown in regression experiments, efficiently controls growth of HPV 16 positive syngeneic tumors. This data demonstrates the potential of this vaccine candidate to control persistent HPV 16 infection that may lead to malignant disease. It also suggests that different sequence rearrangements influence the immunogenecity by an as yet unknown mechanism.
Y1  - 2014
U6  - http://dx.doi.org/10.1371/journal.pone.0113461
SN  - 1932-6203
VL  - 11
IS  - 9
PB  - PLOS
CY  - San Francisco
ER  - 
TY  - JOUR
A1  - Öhlschläger, Peter
A1  - Pes, Michaela
A1  - Osen, Wolfram
A1  - Dürst, Matthias
T1  - An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response / Öhlschläger, Peter ; Pes, Michaela ; Osen, Wolfram ; Dürst, Matthias ; Schneider, Achim ; Gissmann, Lutz ; Kaufman
JF  - Vaccine. 24 (2006), H. 15
Y1  - 2006
SN  - 0264-410X
SP  - 2880
EP  - 2893
ER  - 
TY  - JOUR
A1  - Spiess, Elmar
A1  - Wilfried, Reichardt
A1  - Alvarez, Gerardo
A1  - Gottrup, Marcus
A1  - Öhlschläger, Peter
T1  - An Artificial PAP Gene Breaks Self-tolerance and Promotes Tumor Regression in the TRAMP Model for Prostate Carcinoma
JF  - Molecular Therapy
Y1  - 2011
SN  - 1525-0016
VL  - 20
IS  - 3
SP  - 555
EP  - 564
PB  - Elsevier
CY  - Amsterdam
ER  - 
TY  - JOUR
A1  - Öhlschläger, Peter
A1  - Osen, Wolfram
A1  - Peiler, Tanja
A1  - Caldeira, Sandra
T1  - A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity / Osen, Wolfram ; Peiler, Tanja ; Öhlschläger, Peter ; Caldeira, Sandra ; Faath, Stefan ; Mich
JF  - Vaccine. 19 (2001), H. 20
Y1  - 2001
SN  - 0264-410X
SP  - 4276
EP  - 4286
ER  -